scholarly journals Can cardiovascular risk factors and lifestyle explain the educational inequalities in mortality from ischaemic heart disease and from other heart diseases? 26 year follow up of 50 000 Norwegian men and women

2004 ◽  
Vol 58 (8) ◽  
pp. 705-709 ◽  
Author(s):  
B. H. Strand
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Ischaemic Heart Disease ◽  
Heart Diseases ◽  
Educational Inequalities ◽  
Men And Women ◽  
Inequalities In Mortality

scholarly journals Premature STEMI in Men and Women: Current Clinical Features and Improvements in Management and Prognosis

2021 ◽  
Vol 10 (6) ◽  
pp. 1314
Author(s):  
Rebeca Lorca ◽  
Isaac Pascual ◽  
Andrea Aparicio ◽  
Alejandro Junco-Vicente ◽  
Rut Alvarez-Velasco ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
General Population ◽  
Cardiovascular Risk Factors ◽  
Young Women ◽  
Artery Dissection ◽  
Men And Women ◽  
High Prevalence

Background: Coronary artery disease (CAD) is the most frequent cause of ST-segment elevation myocardial infarction (STEMI). Etiopathogenic and prognostic characteristics in young patients may differ from older patients and young women may present worse outcomes than men. We aimed to evaluate the clinical characteristics and prognosis of men and women with premature STEMI. Methods: A total 1404 consecutive patients were referred to our institution for emergency cardiac catheterization due to STEMI suspicion (1 January 2014–31 December 2018). Patients with confirmed premature (<55 years old in men and <60 in women) STEMI (366 patients, 83% men and 17% women) were included (359 atherothrombotic and 7 spontaneous coronary artery dissection (SCAD)). Results: Premature STEMI patients had a high prevalence of classical cardiovascular risk factors. Mean follow-up was 4.1 years (±1.75 SD). Mortality rates, re-hospitalization, and hospital stay showed no significant differences between sexes. More than 10% of women with premature STEMI suffered SCAD. There were no significant differences between sexes, neither among cholesterol levels nor in hypolipemiant therapy. The global survival rates were similar to that expected in the general population of the same sex and age in our region with a significantly higher excess of mortality at 6 years among men compared with the general population. Conclusion: Our results showed a high incidence of cardiovascular risk factors, a high prevalence of SCAD among young women, and a generally good prognosis after standardized treatment. During follow-up, 23% suffered a major cardiovascular event (MACE), without significant differences between sexes and observed survival at 1, 3, and 6 years of follow-up was 96.57% (95% CI 94.04–98.04), 95.64% (95% CI 92.87–97.35), and 94.5% (95% CI 91.12–97.66). An extra effort to prevent/delay STEMI should be invested focusing on smoking avoidance and optimal hypolipemiant treatment both in primary and secondary prevention.

Iron status and cardiovascular risk factors in patients with haemodialysis versus patients with ischaemic heart disease

Nephrology ◽  
2009 ◽  
Vol 14 (1) ◽  
pp. 65-69
Author(s):  
YI-CHANG CHENG ◽  
WEI-WEN KUO ◽  
CHIEH-HSI WU ◽  
WEN-TONG SHU ◽  
CHIA-HUA KUO ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Ischaemic Heart Disease ◽  
Iron Status

scholarly journals Elevated LH predicts ischaemic heart disease events in older men: the Health in Men Study

2011 ◽  
Vol 164 (4) ◽  
pp. 569-577 ◽  
Author(s):  
Zoë Hyde ◽  
Paul E Norman ◽  
Leon Flicker ◽  
Graeme J Hankey ◽  
Kieran A McCaul ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Ischaemic Heart Disease ◽  
Free Testosterone ◽  
Older Men ◽  
Community Dwelling ◽  
Mass Action ◽  
Age Related

ContextHypogonadism in men is associated with insulin resistance, elevations in pro-inflammatory cytokines and fibrinogen, and an atherogenic lipid profile. However, it is uncertain whether the age-related decline in testosterone is associated with ischaemic heart disease (IHD) events.ObjectiveTo determine whether testosterone and its associated hormones, sex hormone-binding globulin (SHBG) and LH, predict IHD events in older men.DesignProspective cohort study.MethodsBetween 2001 and 2004, 3637 community-dwelling men aged 70–88 years underwent a clinical assessment of cardiovascular risk factors and biochemical assessment of testosterone, SHBG and LH. Free testosterone was calculated using mass action equations. Participants were followed until December 2008 using electronic record linkage to capture IHD events (hospital admission or death).ResultsMean follow-up was 5.1 years. During this period, 618 men (17.0%; 95% confidence interval (CI) 15.8, 18.3%) experienced an event, of which 160 were fatal. Men with higher baseline total or free testosterone levels experienced fewer IHD events (hazard ratio (HR)=0.89; 95% CI 0.82, 0.97 and HR=0.86; 95% CI 0.79, 0.94 for each one s.d. increase in total and free testosterone respectively). These associations were maintained after adjustment for age and waist:hip ratio but did not persist after adjustment for prevalent IHD or other cardiovascular risk factors. SHBG was not associated with IHD events. In contrast, higher LH levels were associated with reduced event-free survival in both univariate (HR=1.15; 95% CI 1.08, 1.22) and adjusted analyses (HR=1.08; 95% CI 1.01, 1.15).ConclusionsDysregulation of the hypothalamic–pituitary–gonadal axis may be a risk factor for IHD. Further studies of men with either elevated LH or low testosterone are warranted.

Cardiovascular risk factors in a Melanesian population apparently free from stroke and ischaemic heart disease: the Kitava study

1994 ◽  
Vol 236 (3) ◽  
pp. 331-340 ◽  
Author(s):  
S. LINDEBERG ◽  
P. NILSSON-EHLE ◽  
A. TERÉNT ◽  
B. VESSBY ◽  
B. SCHERSTÉN
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Ischaemic Heart Disease

scholarly journals Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1811-1811 ◽  
Author(s):  
Hesam Hekmatjou ◽  
Gail J. Roboz ◽  
Ellen K. Ritchie ◽  
Sangmin Lee ◽  
Pinkal Desai ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Ischemic Heart Disease ◽  
Cardiovascular Risk Factors ◽  
Ischemic Heart ◽  
Increased Risk ◽  
Prior Risk

Abstract Arterial thrombosis (AT), including ischemic heart disease, stroke, and peripheral artery occlusive disease (PAOD), have been observed in several studies of CML patients treated with tyrosine kinase inhibitors (TKI’s), most often in patients treated with ponatinib. Reports of AT in patients treated with other TKI’s are based on anecdotal observations and/or studies with relatively short follow-up times and limited data on underlying risk factors. From 1999 to 2014, 408 patients with CML were seen at Weill-Cornell/New York Presbyterian Hospital. Of these, a cohort of 224 patients in chronic phase received ongoing therapy with TKI’s with continuous clinical observation with a median follow-up of 7 years (range 1-15 years). There were 124 (55.4%) men and 100 (44.6%) women with a median age of 52 years (range 21-75 years). Initial therapy with a TKI occurred in 86% whereas 14% had received prior therapy with interferon-alpha and 2% had a prior allogeneic transplant. The initial TKI therapy was imatinib in 82%, nilotinib in 14% and dasatinib in 4%. 49% of patients were treated with only 1 TKI, 21% with 2 TKI’s and 30% with > 2 TKI’s. Over the course of therapy, overall 82% of patients were exposed to imatinib, 33.9% to nilotinib, 25% to dasatinib and 2.2% to ponatinib. Information on pre-treatment cardiovascular risk factors which included; a history of a prior AT, diabetes, hyperlipidemia, hypertension and smoking, were available on all patients. Prior AT occurred in 7.5%; 25% had 1 risk factor and 20.6% had 2 or more risk factors. Overall AT was observed in 7.1% (95% CI = 3.8%, 10.5%) of all patients and there were no deaths associated with AT. Ischemic heart disease occurred in 4.9%, a stroke in 0.4% and PAOD in 1.8%. The median time from start of TKI therapy to development of AT was 7 years (range 4-14). The median age of patients who developed AT was 68 years (range 47-80). AT occurred predominantly in patients with pre-existing risk factors; the incidence was 14.6% in patients with prior risk factors whereas only 1.6% of patients without risk factors developed this complication (p<0.0001). In 16 /224 patients, 17 AT’s occurred; 10 while on treatment with imatinib, 5 on nilotinib, 1 on dasatinib and 2 on ponatinib. By overall TKI exposure, AT occurred in 5.4 % of patients exposed to imatinib 6.6% exposed to nilotinib and 1.8% exposed to dasatinib (p=not significant). Apart from ponatinib, neither the initial TKI used, the overall exposure or length of exposure to TKI’s, or the number of TKI’s administered were associated with an increased risk of AT. These data would suggest that the development of AT is uncommon in patients without prior risk factors and occurs with equal frequency in patients exposed to either imatinib or nilotinib. Additional data are needed to conclusively determine whether treatment with a TKI (excluding ponatinib) is an independent risk factor for the development of AT in CML patients. Importantly, identification of the mechanism(s) associated with TKI-related AT in CML patients are needed to plan preventive measures, particularly in patients with preexisting risk factors. Disclosures Roboz: Novartis: Consultancy; Agios: Consultancy; Celgene: Consultancy; Glaxo SmithKline: Consultancy; Astra Zeneca: Consultancy; Sunesis: Consultancy; Novartis: Consultancy; Teva Oncology: Consultancy; Astex: Consultancy. Allen-Bard:Novartis: Speakers Bureau. Feldman:Novartis: Honoraria, Research Funding, Speakers Bureau; Ariad: Honoraria, Speakers Bureau.

Sign in / Sign up

Export Citation Format

Share Document